While YAP1 has been previously proposed as the defining feature of a distinct SCLC subtype (SCLC-Y), accumulating evidence suggests that YAP1 activation is more accurately described as a therapy-induced or resistance-associated phenotype rather than a de novo molecular subtype. The gene discussed is YAP1; the disease is small cell lung carcinoma.